Advances two clinical programs through topline data across four indications Progresses two preclinical programs to potential lead candidate selection Brings total funding since inception to $140 million SEATTLE and CAMBRIDGE, UK –(BUSINESS WIRE) – May 24, 2021 – Eliem Therapeutics, Inc., a